000963 华东医药
已收盘 07-22 15:00:00
资讯
新帖
简况
最高减重20%!礼来“替尔泊肽”在华获批,效果强过司美格鲁肽?
格隆汇 · 07-22 10:20
最高减重20%!礼来“替尔泊肽”在华获批,效果强过司美格鲁肽?
华东医药(000963.SZ)拟斥5.28亿元收购恒霸药业100%股权 丰富外用制剂产品管线
智通财经 · 07-21 17:09
华东医药(000963.SZ)拟斥5.28亿元收购恒霸药业100%股权 丰富外用制剂产品管线
华东医药最新公告:子公司签署QX005N产品合作开发及市场推广服务协议
证券之星 · 07-21 17:01
华东医药最新公告:子公司签署QX005N产品合作开发及市场推广服务协议
华东医药(000963.SZ)全资子公司签署QX005N产品合作开发及市场推广服务协议
智通财经 · 07-21 17:01
华东医药(000963.SZ)全资子公司签署QX005N产品合作开发及市场推广服务协议
华东医药最新公告:子公司博华制药收购恒霸药业100%股权
证券之星 · 07-21 16:41
华东医药最新公告:子公司博华制药收购恒霸药业100%股权
华东医药独家引进澳宗生物依达拉奉片,加码创新领域布局
证券之星 · 07-14
华东医药独家引进澳宗生物依达拉奉片,加码创新领域布局
华东医药最新公告:子公司与澳宗生物签署产品独家许可协议
证券之星 · 07-14
华东医药最新公告:子公司与澳宗生物签署产品独家许可协议
华东医药(000963.SZ)与澳宗生物签署依达拉奉片独家许可协议 丰富心脑血管领域产品线
智通财经 · 07-14
华东医药(000963.SZ)与澳宗生物签署依达拉奉片独家许可协议 丰富心脑血管领域产品线
非酒精性脂肪性肝炎(NASH)概念盘中拉升,华东医药涨2.12%
自选股智能写手 · 07-05
非酒精性脂肪性肝炎(NASH)概念盘中拉升,华东医药涨2.12%
华东医药:公司后续将根据项目情况选择海外临床开发路径
证券之星 · 07-04
华东医药:公司后续将根据项目情况选择海外临床开发路径
华东医药:塞纳帕利的上市申请已于2023年8月被国家药品监督管理局(NMPA)受理
证券之星 · 07-02
华东医药:塞纳帕利的上市申请已于2023年8月被国家药品监督管理局(NMPA)受理
华东医药(000963.SZ):注射用HDM2005药品临床试验申请获得美国FDA批准
智通财经 · 07-01
华东医药(000963.SZ):注射用HDM2005药品临床试验申请获得美国FDA批准
华东医药最新公告:注射用HDM2005药品临床试验申请获得美国FDA批准
证券之星 · 07-01
华东医药最新公告:注射用HDM2005药品临床试验申请获得美国FDA批准
华东医药:2024年一季度,公司工业微生物板块收入保持稳定增长,同比增长23.00%
证券之星 · 06-27
华东医药:2024年一季度,公司工业微生物板块收入保持稳定增长,同比增长23.00%
更新版 1-诺和诺德的司美格鲁肽在中国获准“名正言顺”用来减肥,A股概念股逆市上扬
Reuters · 06-25
更新版 1-诺和诺德的司美格鲁肽在中国获准“名正言顺”用来减肥,A股概念股逆市上扬
华东医药:DR30303目前尚处于临床一期阶段
证券之星 · 06-13
华东医药:DR30303目前尚处于临床一期阶段
华东医药(000963)6月7日主力资金净卖出2069.99万元
证券之星 · 06-11
华东医药(000963)6月7日主力资金净卖出2069.99万元
华东医药(000963.SZ):一类生物新药注射用HDM2005获得药物临床试验批准
智通财经网 · 06-04
华东医药(000963.SZ):一类生物新药注射用HDM2005获得药物临床试验批准
华东医药:目前公司工业微生物板块美琪健康有维生素K2产品在产
证券之星 · 06-04
华东医药:目前公司工业微生物板块美琪健康有维生素K2产品在产
华东医药:公司目前无您所说的计划
证券之星 · 05-31
华东医药:公司目前无您所说的计划
加载更多
公司概况
公司名称:
华东医药股份有限公司
所属行业:
零售业
上市日期:
2000-01-27
主营业务:
华东医药股份有限公司主营业务是药品的研发、生产和销售。主要产品包括医药工业、医药商业、医美、工业微生物。公司医药工业深耕于专科,慢病用药及特殊用药领域的研发,生产和销售,并形成以慢性肾病,移植免疫,内分泌,消化系统等领域为主的核心产品管线。公司连续第十四年上榜财富中文网评选的《财富》中国500强,位列357位;入选米内网“2021年度中国医药工业百强”系列榜单,蝉联2021年度中国化药百强企业TOP10;荣膺全国工商联“2021年度中国医药制造业百强”“2021年度中国医药商业百强”,中国企业联合会“2022中国民营企业500强”“2022中国服务业企业500强”,荣获药智网“2022中国药品研发综合实力排行榜TOP100”“2022中国化药研发实力排行榜TOP100”。
发行价格:
5.76
{"stockData":{"symbol":"000963","market":"SZ","secType":"STK","nameCN":"华东医药","latestPrice":29.56,"timestamp":1721631786000,"preClose":29.48,"halted":0,"volume":10964333,"delay":0,"floatShares":1751000000,"shares":1754000000,"eps":1.6793,"marketStatus":"已收盘","marketStatusCode":5,"change":0.08,"latestTime":"07-22 15:00:00","open":29.35,"high":29.97,"low":29.31,"amount":325000000,"amplitude":0.0224,"askPrice":29.56,"askSize":36,"bidPrice":29.55,"bidSize":28,"shortable":0,"etf":0,"ttmEps":1.6793,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721698200000},"adr":0,"adjPreClose":29.48,"symbolType":"stock","openAndCloseTimeList":[[1721611800000,1721619000000],[1721624400000,1721631600000]],"highLimit":32.43,"lowLimit":26.53,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1754327548,"pbRate":2.36,"roa":"--","roe":"4.01%","epsLYR":1.6219,"committee":-0.202993,"marketValue":51858000000,"floatMarketCap":51757000000,"peRate":17.602573,"changeRate":0.0027,"turnoverRate":0.0063,"status":0},"requestUrl":"/m/hq/s/000963","defaultTab":"news","newsList":[{"id":"2453786850","title":"最高减重20%!礼来“替尔泊肽”在华获批,效果强过司美格鲁肽?","url":"https://stock-news.laohu8.com/highlight/detail?id=2453786850","media":"格隆汇","labels":["Product Release","Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2453786850?lang=zh_cn&edition=full","pubTime":"2024-07-22 10:20","pubTimestamp":1721614814,"startTime":"0","endTime":"0","summary":"竞争白热化?","market":"us","thumbnail":"https://img3.gelonghui.com/1b662-9eab396d-85aa-4a35-807e-33d8ee710c4d.jpg?guru_height=908&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/1b662-9eab396d-85aa-4a35-807e-33d8ee710c4d.jpg?guru_height=908&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/869192","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release,Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK4534","LU1551013342.USD","LU1623119135.USD","LU2328871848.SGD","LU0122379950.USD","NVO","LU0256863811.USD","300199","603087","IE00BJT1NW94.SGD","BK4532","LU0096364046.USD","LU1551013425.SGD","IE00BJJMRZ35.SGD","LU1093756325.SGD","LU0471298694.HKD","BK0183","LU0097036916.USD","LU0385154629.USD","000963","BK0187","BK0239","LU0061475181.USD","IE0002141913.USD","LU0109391861.USD","LU1804176565.USD","LI","BK4533","BK4516","LU0708995401.HKD","LU1280957306.USD","BK0188","LU0943347566.SGD","IE00BJLML261.HKD","IE00B1BXHZ80.USD","LU1061106388.HKD","BK0077","GB00BDT5M118.USD","IE0009355771.USD","LU0820561909.HKD","LU0114720955.EUR","BK0175","BK4007","LU1093756168.USD","LU0079474960.USD","LU1035775433.USD","LU0882574055.USD","LU0058720904.USD","LU0094547139.USD","IE0004445239.USD"],"gpt_icon":1},{"id":"2453226197","title":"华东医药(000963.SZ)拟斥5.28亿元收购恒霸药业100%股权 丰富外用制剂产品管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2453226197","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453226197?lang=zh_cn&edition=full","pubTime":"2024-07-21 17:09","pubTimestamp":1721552971,"startTime":"0","endTime":"0","summary":"据悉,贵州恒霸药业有限责任公司成立于1995年,是一家以研究开发苗族民族药品为主,集中药材种植、科研、生产、销售为一体的国家高新技术企业。目前在生产和销售的主要产品为伤科灵喷雾剂、痹痛宁胶囊。此外,伤科灵喷雾剂是独家品种、处方药/OTC双跨品种、国家医保乙类药品。本次公司收购恒霸药业,获得伤科灵喷雾剂等产品,将进一步丰富公司外用制剂产品管线,强化公司外用制剂领域核心竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153621.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2328871848.SGD","BK0187","BK0175","BK0132","BK0196","BK0209","LU1969619763.USD","BK0183","000963","BK0188"],"gpt_icon":0},{"id":"2453226615","title":"华东医药最新公告:子公司签署QX005N产品合作开发及市场推广服务协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2453226615","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453226615?lang=zh_cn&edition=full","pubTime":"2024-07-21 17:01","pubTimestamp":1721552496,"startTime":"0","endTime":"0","summary":"华东医药公告,7月19日,公司全资子公司杭州中美华东制药有限公司(简称“中美华东”)与公司参股的香港上市公司江苏荃信生物医药股份有限公司(简称“荃信生物”)签署QX005N产品的合作开发及市场推广服务协议。中美华东获得荃信生物QX005N产品在中国内地、香港、澳门和台湾地区(简称“授权区域”)的排他共同合作开发权,独家市场推广的选择权及上市许可持有人转让的优先合作权。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072100006466.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0187","BK0175","BK0209","BK0132","LU1969619763.USD","000963","LU2328871848.SGD","BK0188","BK0183"],"gpt_icon":0},{"id":"2453266732","title":"华东医药(000963.SZ)全资子公司签署QX005N产品合作开发及市场推广服务协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2453266732","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453266732?lang=zh_cn&edition=full","pubTime":"2024-07-21 17:01","pubTimestamp":1721552491,"startTime":"0","endTime":"0","summary":"中美华东获得荃信生物QX005N产品在中国大陆、香港、澳门和台湾地区的排他共同合作开发权,独家市场推广的选择权及上市许可持有人转让的优先合作权。若未来中美华东行使独家市场推广选择权,中美华东将负责QX005N产品在授权区域内的独家市场推广服务,荃信生物负责QX005N产品及临床试验样品的独家生产、供应及质量控制。目前,QX005N注射液针对成人中重度特应性皮炎及结节性痒疹的两项国内III期临床试验均在入组中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153618.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2328871848.SGD","000963","BK0188","BK0187","LU1969619763.USD","BK0196","BK0175","BK0132","BK0183","BK0209"],"gpt_icon":0},{"id":"2453225755","title":"华东医药最新公告:子公司博华制药收购恒霸药业100%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2453225755","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453225755?lang=zh_cn&edition=full","pubTime":"2024-07-21 16:41","pubTimestamp":1721551276,"startTime":"0","endTime":"0","summary":"华东医药公告,子公司博华制药收购贵州恒霸药业有限责任公司100%股权,交易基础价款5.2847亿元,并将根据协议约定支付浮动对价。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072100006444.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0196","01477","BK0187","BK0175","BK0209","BK0132","BK1191","LU1969619763.USD","000963","LU2328871848.SGD","BK0188","BK0183"],"gpt_icon":0},{"id":"2451684974","title":"华东医药独家引进澳宗生物依达拉奉片,加码创新领域布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2451684974","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451684974?lang=zh_cn&edition=full","pubTime":"2024-07-14 18:38","pubTimestamp":1720953500,"startTime":"0","endTime":"0","summary":"此次华东医药独家引入的TTYP01片是全球唯一依达拉奉口服制剂,是澳宗生物基于已上市依达拉奉注射剂型的安全性和有效性数据,通过创新技术改变其给药途径,从而开发出TTYP01片,克服了该药在口服制剂开发领域的难题。华东医药此次引进TTYP01片将于年内申报NDA,将进一步丰富公司心脑血管领域产品线,与公司现有产品实现高度协同。华东医药正在积极推进其相关的临床注册工作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://news.stockstar.com/IG2024071400002963.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2328871848.SGD","000963","BK0188","BK0187","LU1969619763.USD","BK0196","BK0175","BK0132","BK0183","BK0209"],"gpt_icon":0},{"id":"2451686631","title":"华东医药最新公告:子公司与澳宗生物签署产品独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2451686631","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451686631?lang=zh_cn&edition=full","pubTime":"2024-07-14 17:39","pubTimestamp":1720949973,"startTime":"0","endTime":"0","summary":"华东医药公告,全资子公司中美华东与苏州澳宗生物科技有限公司签订产品独家许可协议。中美华东获得澳宗生物的TTYP01片所有适应症在中国大陆、香港、澳门和台湾地区的独家许可,包括开发、注册、生产及商业化权益。中美华东将向澳宗生物支付1亿元首付款,最高不超过11.85亿元的开发、注册及销售里程碑付款,以及分级最高达两位数的净销售额提成费。TTYP01片是澳宗生物自主开发的改良型新药,急性缺血性脑卒中适应症已完成国内临床Ⅲ期研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071400002744.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","LU2328871848.SGD","BK0132","BK0188","BK0175","BK0183","LU1969619763.USD","BK0209","BK0196","000963"],"gpt_icon":0},{"id":"2451685687","title":"华东医药(000963.SZ)与澳宗生物签署依达拉奉片独家许可协议 丰富心脑血管领域产品线","url":"https://stock-news.laohu8.com/highlight/detail?id=2451685687","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451685687?lang=zh_cn&edition=full","pubTime":"2024-07-14 17:05","pubTimestamp":1720947930,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华东医药 发布公告,2024年7月12日,公司全资子公司杭州中美华东制药有限公司与苏州澳宗生物科技有限公司签订了产品独家许可协议。中美华东获得澳宗生物的TTYP01片所有适应症在中国大陆、香港、澳门和台湾地区的独家许可,包括开发、注册、生产及商业化权益。公司表示,本次合作将进一步丰富公司心脑血管领域产品线,与公司现有产品实现高度协同。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1150592.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","BK0209","000963","BK0175","BK0187","BK0196","BK0132","BK0188","LU1969619763.USD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2449528829","title":"非酒精性脂肪性肝炎(NASH)概念盘中拉升,华东医药涨2.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2449528829","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449528829?lang=zh_cn&edition=full","pubTime":"2024-07-05 09:49","pubTimestamp":1720144175,"startTime":"0","endTime":"0","summary":"07月05日,非酒精性脂肪性肝炎(NASH)概念盘中拉升,截至09点49分,非酒精性脂肪性肝炎(NASH)概念整体指数上涨0.54%,报964.550点。从个股上来看,该概念的成分股中,华东医药涨2.12%,天士力、微芯生物、众生药业涨幅居前。从资金上来看,截止发稿,非酒精性脂肪性肝炎(NASH)概念主力净流入为-2879.04万,其中天士力受到资金热捧,主力净流入157.09万;拉长时间线来看,该板块近20日主力资金净流入-15.33亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240705094935af90a7ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240705094935af90a7ac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0187","LU2328871848.SGD","BK0132","BK0188","BK0175","BK0239","BK0028","BK0183","LU1969619763.USD","BK0209","BK0012","000963","BK0196","600535"],"gpt_icon":0},{"id":"2448941768","title":"华东医药:公司后续将根据项目情况选择海外临床开发路径","url":"https://stock-news.laohu8.com/highlight/detail?id=2448941768","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448941768?lang=zh_cn&edition=full","pubTime":"2024-07-04 17:03","pubTimestamp":1720083804,"startTime":"0","endTime":"0","summary":"证券之星消息,华东医药07月04日在投资者关系平台上答复投资者关心的问题。公司近一年多获得了3个创新药的FDA临床批件,创新能力的提升有目共睹。请问后续海外临床公司会自己推进入组,还是会找合作方来推进华东医药董秘:您好!公司后续将根据项目情况选择海外临床开发路径。投资者:公司之前公告的MediBeacon肾小球滤过率动态监测系统于2023年7月向FDA上市申请正式受理,有望于 2024 年上半年获批。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070400033906.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0209","BK0183","LU2328871848.SGD","000963","LU1969619763.USD","BK0187","BK0196","BK0132","BK0175"],"gpt_icon":0},{"id":"2448136190","title":"华东医药:塞纳帕利的上市申请已于2023年8月被国家药品监督管理局(NMPA)受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2448136190","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448136190?lang=zh_cn&edition=full","pubTime":"2024-07-02 18:04","pubTimestamp":1719914686,"startTime":"0","endTime":"0","summary":"证券之星消息,华东医药07月02日在投资者关系平台上答复投资者关心的问题。公司后续的分红方案请您关注公司的相关公告。不知道上市推进到哪一步了?塞纳帕利的上市申请已于2023年8月被国家药品监督管理局受理。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070200028176.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0183","BK0196","LU1969619763.USD","BK0209","BK0187","LU2328871848.SGD","000963","BK0132","BK0175"],"gpt_icon":0},{"id":"2448693079","title":"华东医药(000963.SZ):注射用HDM2005药品临床试验申请获得美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2448693079","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448693079?lang=zh_cn&edition=full","pubTime":"2024-07-01 17:04","pubTimestamp":1719824676,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华东医药 发布公告,近日,公司全资子公司杭州中美华东制药有限公司收到美国食品药品监督管理局通知,由中美华东申报的注射用HDM2005药品临床试验申请已获得美国FDA批准,可在美国开展I期临床试验。HDM2005已经在临床前研究、药代动力学研究及安全性评价中展现出良好的抗肿瘤活性和安全性。本次注射用HDM2005临床试验获批,是该款产品研发进程中的重要里程碑,将进一步提升公司在ADC肿瘤治疗领域的核心竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1143597.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2328871848.SGD","03347","BK1576","BK0187","BK0175","BK0132","BK0196","BK0209","LU1969619763.USD","BK0183","000963","BK0188","BK1141","BK1583"],"gpt_icon":0},{"id":"2448966786","title":"华东医药最新公告:注射用HDM2005药品临床试验申请获得美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2448966786","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448966786?lang=zh_cn&edition=full","pubTime":"2024-07-01 16:50","pubTimestamp":1719823831,"startTime":"0","endTime":"0","summary":"华东医药公告,全资子公司中美华东申报的注射用HDM2005药品临床试验申请已获得美国FDA批准,可在美国开展I期临床试验。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070100021687.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0132","BK1576","LU1969619763.USD","BK1141","BK0183","BK0188","BK1583","03347","LU2328871848.SGD","BK0187","BK0209","000963","BK0196"],"gpt_icon":0},{"id":"2446585143","title":"华东医药:2024年一季度,公司工业微生物板块收入保持稳定增长,同比增长23.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2446585143","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446585143?lang=zh_cn&edition=full","pubTime":"2024-06-27 17:03","pubTimestamp":1719479004,"startTime":"0","endTime":"0","summary":"2024年一季度,公司工业微生物板块收入保持稳定增长,同比增长23.00%。工业微生物板块二季度的经营情况请您关注公司后续发布的2024年半年度报告。华东医药相对于同业竞争公司,供应链的优势体现在哪些地方。华东医药供应链公司首批列入“省级供应链创新与应用试点企业”,通过利用现代化手段,实现了冷链车辆、温度实时监测,实现药品接收、存储、配用等过程的智能化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062700032931.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2328871848.SGD","BK0187","BK0175","BK0132","BK0196","BK0209","LU1969619763.USD","BK0183","000963","BK0188"],"gpt_icon":0},{"id":"2446471897","title":"更新版 1-诺和诺德的司美格鲁肽在中国获准“名正言顺”用来减肥,A股概念股逆市上扬","url":"https://stock-news.laohu8.com/highlight/detail?id=2446471897","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446471897?lang=zh_cn&edition=full","pubTime":"2024-06-25 17:39","pubTimestamp":1719308396,"startTime":"0","endTime":"0","summary":" 路透上海6月25日 - 丹麦诺和诺德 的司美格鲁肽号称“减肥神药”,在爱美人士中走红。现在这款药物终于在中国原研专利到期前,被批准用于治疗超重和肥胖症。这意味着中国也成为继日本之后,第二个批准诺和诺德的司美格鲁肽治疗肥胖的亚洲国家。诺和诺德大中国区高管在3月表示,在中国推出的用于减肥的司美格鲁肽最开始将以自费患者为主。诺和诺德的司美格鲁肽在中国的专利将于2026年3月20日到期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","300199","BK0183","BK4534","IE0002141913.USD","LU1988902786.USD","LU1551013342.USD","LU2491049909.HKD","LU1804176565.USD","LU2148510915.USD","IE0004445239.USD","LU0882574055.USD","LU0122379950.USD","GB00BDT5M118.USD","01801","LU2237438978.USD","LU2264538146.SGD","LU1064130708.USD","LLY","LU1280957306.USD","LU1814569148.SGD","399300","LU1057294990.SGD","LU0289739699.SGD","BK4533","BK0077","BK4007","LU0109391861.USD","LU2468319806.SGD","LU0672654240.SGD","BK0070","159982","000963","BK0175","IE00B1BXHZ80.USD","BK0239","LU1551013425.SGD","BK1589","LU1023059063.AUD","300122","LU0256863811.USD","LU0417517546.SGD","LU0058720904.USD","LU0708995401.HKD","LU2491050071.SGD","IE00BJT1NW94.SGD","LU0079474960.USD","LU0061475181.USD","IE00BJJMRZ35.SGD","03692"],"gpt_icon":0},{"id":"2443508002","title":"华东医药:DR30303目前尚处于临床一期阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2443508002","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443508002?lang=zh_cn&edition=full","pubTime":"2024-06-13 18:04","pubTimestamp":1718273064,"startTime":"0","endTime":"0","summary":"证券之星消息,华东医药06月13日在投资者关系平台上答复投资者关心的问题。投资者:你好,董秘,道尔生物的DR30303进入一期临床两年了,请问预计什么时候进入二期,另外该药物的一期临床数据怎么样。DR30303目前尚处于临床一期阶段。公司暂无在本次ADA大会上做报告的计划。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061300034294.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","BK0132","BK0183","LU2328871848.SGD","BK0196","000963","BK0188","BK0175","BK0187","LU1969619763.USD"],"gpt_icon":0},{"id":"2442804259","title":"华东医药(000963)6月7日主力资金净卖出2069.99万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2442804259","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442804259?lang=zh_cn&edition=full","pubTime":"2024-06-11 09:22","pubTimestamp":1718068966,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年6月7日收盘,华东医药报收于31.37元,下跌1.78%,换手率0.4%,成交量7.01万手,成交额2.21亿元。近5日资金流向一览见下表:华东医药融资融券信息显示,融资方面,当日融资买入1813.35万元,融资偿还2774.73万元,融资净偿还961.38万元。华东医药主营业务:医药工业、医药商业、医美、工业微生物四大业务板块。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061100002298.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0132","LU1969619763.USD","BK0183","BK0188","LU2328871848.SGD","BK0187","BK0209","000963","BK0196"],"gpt_icon":0},{"id":"2440404027","title":"华东医药(000963.SZ):一类生物新药注射用HDM2005获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2440404027","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440404027?lang=zh_cn&edition=full","pubTime":"2024-06-04 17:20","pubTimestamp":1717492814,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华东医药 发布公告,近日,公司全资子公司杭州中美华东制药有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,由中美华东申报的注射用HDM2005临床试验申请获得批准。HDM2005已经在临床前的药效学研究、药代动力学研究及安全性评价中展现出良好的抗肿瘤活性和安全性。本次注射用HDM2005临床试验获批,是该款产品研发进程中的重要里程碑,将进一步提升公司在ADC肿瘤治疗领域的核心竞争力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1130782.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0196","BK1141","BK0188","03347","BK1576","BK0175","BK0187","BK0209","BK0132","LU1969619763.USD","BK1583","LU2328871848.SGD","000963","BK0183"],"gpt_icon":0},{"id":"2440046704","title":"华东医药:目前公司工业微生物板块美琪健康有维生素K2产品在产","url":"https://stock-news.laohu8.com/highlight/detail?id=2440046704","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440046704?lang=zh_cn&edition=full","pubTime":"2024-06-04 17:04","pubTimestamp":1717491854,"startTime":"0","endTime":"0","summary":"证券之星消息,华东医药06月04日在投资者关系平台上答复投资者关心的问题。目前公司工业微生物板块美琪健康有维生素K2产品在产。目前该业务对公司整体影响较小,敬请投资者注意风险,理性投资。望贵公司将在维生素市场中占据有利地位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060400033198.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2328871848.SGD","000963","BK0188","BK0187","LU1969619763.USD","BK0196","BK0175","BK0132","BK0183","BK0209"],"gpt_icon":0},{"id":"2439696545","title":"华东医药:公司目前无您所说的计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2439696545","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439696545?lang=zh_cn&edition=full","pubTime":"2024-05-31 18:03","pubTimestamp":1717149828,"startTime":"0","endTime":"0","summary":"证券之星消息,华东医药(000963)05月31日在投资者关系平台上答复投资者关心的问题。投资者:目前,生活压力较大。乌灵胶囊有很好的治疗作用。经查询乌灵胶囊中药保护品种证书已于2020年到期。请问贵公司是否有计划利用药监局同名同方政策进行类似药品的申报工作。华东医药董秘:您好!公司目前无您所说的计划。感谢您的关注!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024053100036319.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0209","BK0196","LU1969619763.USD","BK0183","BK0188","LU2328871848.SGD","000963","BK0187","BK0132"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2000-01-27","address":"浙江省杭州市拱墅区中山北路439号4、7楼","stockEarnings":[{"period":"1week","weight":0.0683},{"period":"1month","weight":0.0253},{"period":"3month","weight":-0.0874},{"period":"6month","weight":-0.0843},{"period":"1year","weight":-0.3142},{"period":"ytd","weight":-0.2738}],"companyName":"华东医药股份有限公司","boardCode":"AI0052","perCapita":"18659股","boardName":"零售业","registeredCapital":"175432万元","compareEarnings":[{"period":"1week","weight":-0.0033},{"period":"1month","weight":-0.0113},{"period":"3month","weight":-0.0191},{"period":"6month","weight":0.0509},{"period":"1year","weight":-0.0642},{"period":"ytd","weight":-0.0036}],"survey":" 华东医药股份有限公司主营业务是药品的研发、生产和销售。主要产品包括医药工业、医药商业、医美、工业微生物。公司医药工业深耕于专科,慢病用药及特殊用药领域的研发,生产和销售,并形成以慢性肾病,移植免疫,内分泌,消化系统等领域为主的核心产品管线。公司连续第十四年上榜财富中文网评选的《财富》中国500强,位列357位;入选米内网“2021年度中国医药工业百强”系列榜单,蝉联2021年度中国化药百强企业TOP10;荣膺全国工商联“2021年度中国医药制造业百强”“2021年度中国医药商业百强”,中国企业联合会“2022中国民营企业500强”“2022中国服务业企业500强”,荣获药智网“2022中国药品研发综合实力排行榜TOP100”“2022中国化药研发实力排行榜TOP100”。","serverTime":1721668648558,"listedPrice":5.76,"stockholders":"93834人(较上一季度增加21.62%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华东医药(000963)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华东医药(000963)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华东医药,000963,华东医药股票,华东医药股票老虎,华东医药股票老虎国际,华东医药行情,华东医药股票行情,华东医药股价,华东医药股市,华东医药股票价格,华东医药股票交易,华东医药股票购买,华东医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华东医药(000963)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华东医药(000963)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}